Birner Dental Management Services (BDMS) 10-Q 14 Aug 17 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 09, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	BIRNER DENTAL MANAGEMENT SERVICES INC
Entity Central Index Key	948,072
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		1,872,761
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
CURRENT ASSETS:
Cash	$ 204,894	$ 157,923
Accounts receivable, net of allowance for doubtful accounts of approximately $410,000 and $430,000, respectively	3,816,007	3,212,190
Note receivable	34,195	34,195
Income tax receivable	46,992	0
Prepaid expenses and other assets	729,319	759,749
Total current assets	4,831,407	4,164,057
PROPERTY AND EQUIPMENT, net	6,064,701	7,279,436
OTHER NONCURRENT ASSETS:
Intangible assets, net	6,298,335	6,721,084
Deferred charges and other assets	163,991	155,741
Note receivable	15,548	31,051
Total assets	17,373,982	18,351,369
CURRENT LIABILITIES:
Accounts payable	3,972,215	2,723,473
Accrued expenses	865,762	925,776
Accrued payroll and related expenses	2,422,999	2,164,758
Current maturities of long-term debt	8,896,864	2,500,000
Total current liabilities	16,157,840	8,314,007
LONG-TERM LIABILITIES:
Deferred tax liability, net	587,847	1,174,416
Long-term debt	0	7,351,006
Other long-term obligations	1,063,087	1,081,655
Total liabilities	17,808,774	17,921,084
SHAREHOLDERS' EQUITY (DEFICIT):
Preferred Stock, no par value, 10,000,000 shares authorized; none outstanding	0	0
Common Stock, no par value, 20,000,000 shares authorized; 1,860,261 and 1,872,761 shares issued and outstanding, respectively	1,876,256	1,615,001
Accumulated deficit	(2,311,048)	(1,184,716)
Total shareholders' equity (deficit)	(434,792)	430,285
Total liabilities and shareholders' equity (deficit)	$ 17,373,982	$ 18,351,369

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
CURRENT ASSETS:
Allowance for doubtful accounts	$ 430,000	$ 410,000
SHAREHOLDERS' EQUITY (DEFICIT):
Preferred Stock, par value (in dollars per share)	$ 0	$ 0
Preferred Stock, authorized (in shares)	10,000,000	10,000,000
Preferred Stock, outstanding (in shares)	0	0
Common Stock, par value (in dollars per share)	$ 0	$ 0
Common Stock, authorized (in shares)	20,000,000	20,000,000
Common Stock, issued (in shares)	1,872,761	1,860,261
Common Stock, outstanding (in shares)	1,872,761	1,860,261

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2017		Jun. 30, 2016		Jun. 30, 2017		Jun. 30, 2016
REVENUE:
Dental practice revenue	$ 13,753,775		$ 14,654,768		$ 28,372,479		$ 30,021,310
Capitation revenue	1,025,443		1,230,372		2,067,419		2,295,063
Total Revenue	14,779,218		15,885,140		30,439,898		32,316,373
DIRECT EXPENSES:
Clinical salaries and benefits	9,252,188		9,450,678		18,718,487		19,321,628
Dental supplies	672,187		732,657		1,300,592		1,457,930
Laboratory fees	931,760		908,029		1,812,901		1,779,644
Occupancy	1,652,889		1,553,800		3,203,149		3,120,605
Advertising and marketing	167,467		155,208		337,371		314,078
Depreciation and amortization	913,693		1,018,043		1,878,494		2,038,133
General and administrative	1,287,012		1,341,988		2,550,637		2,745,198
Total Direct Expenses	14,877,196		15,160,403		29,801,631		30,777,216
Contribution from dental offices	(97,978)		724,737		638,267		1,539,157
CORPORATE EXPENSES:
General and administrative	1,011,917	[1]	970,860	[1]	1,971,374	[2]	1,847,766	[2]
Stock Grant	175,000	[3]	0		175,000	[3]	0
Depreciation and amortization	38,864		56,080		84,948		118,880
OPERATING LOSS	(1,323,759)		(302,203)		(1,593,055)		(427,489)
OTHER EXPENSE:
Interest expense, net	94,414		75,550		166,838		114,873
LOSS BEFORE INCOME TAXES	(1,418,173)		(377,753)		(1,759,893)		(542,362)
Income tax benefit	(516,899)		(147,324)		(633,561)		(211,522)
NET LOSS	$ (901,274)		$ (230,429)		$ (1,126,332)		$ (330,840)
Net loss per share of Common Stock - Basic (in dollars per share)	$ (0.48)		$ (0.12)		$ (0.60)		$ (0.18)
Net loss per share of Common Stock - Diluted (in dollars per share)	$ (0.48)		$ (0.12)		$ (0.60)		$ (0.18)
Weighted average number of shares of Common Stock and dilutive securities:
Basic (in shares)	1,866,580		1,860,261		1,863,746		1,860,372
Diluted (in shares)	1,866,580		1,860,261		1,863,746		1,860,372
[1]	Corporate expense - general and administrative includes $44,102 and $51,019 of stock-based compensation expense pursuant to ASC Topic 718 for the quarters ended June 30, 2016 and 2017, respectively.
[2]	Corporate expense - general and administrative includes $90,809 and $86,255 of stock-based compensation expense pursuant to ASC Topic 718 for the six months ended June 30, 2016 and 2017, respectively.
[3]	The Company issued 12,500 shares of Common Stock under a settlement agreement with an activist shareholder group. The shares were valued at $175,000 based on the closing price of the Common Stock on the date of the grant.

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) [Abstract]
Common stock issued (in shares)	12,500
Value of common stock issued	$ 175,000		$ 175,000
General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense	$ 51,019	$ 44,102	$ 86,255	$ 90,809

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (DEFICIT) (UNAUDITED) - 6 months ended Jun. 30, 2017 - USD ($)	Common Stock [Member]	Accumulated Deficit [Member]	Total
BALANCES at Dec. 31, 2016	$ 1,615,001	$ (1,184,716)	$ 430,285
BALANCES (in shares) at Dec. 31, 2016	1,860,261		1,860,261
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock grant	$ 175,000	0	$ 175,000
Stock grant (in shares)	12,500
Stock-based compensation expense	$ 86,255	0	86,255
Net loss	0	(1,126,332)	(1,126,332)
BALANCES at Jun. 30, 2017	$ 1,876,256	$ (2,311,048)	$ (434,792)
BALANCES (in shares) at Jun. 30, 2017	1,872,761		1,872,761

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	6 Months Ended
	Jun. 30, 2017		Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,126,332)		$ (330,840)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	1,963,442		2,157,013
Stock-based compensation expense	86,255		90,809
Provision for doubtful accounts	362,087		401,080
Benefit from deferred income taxes	(586,569)		(309,238)
Stock grant	175,000	[1]	0
Changes in assets and liabilities:
Accounts receivable	(965,904)		(602,176)
Prepaid expenses and other assets	30,430		(188,973)
Deferred charges and other assets	(8,250)		0
Accounts payable	1,248,742		(139,895)
Accrued expenses	(60,014)		(236,841)
Accrued payroll and related expenses	258,241		102,963
Income taxes payable (receivable)	(46,992)		179,217
Other long-term obligations	(18,568)		156,287
Net cash provided by operating activities	1,311,568		1,279,406
CASH FLOWS USED IN INVESTING ACTIVITIES:
Capital expenditures	(325,958)		(418,330)
Note receivable	15,503		14,603
Net cash used in investing activities	(310,455)		(403,727)
CASH FLOWS USED IN FINANCING ACTIVITIES:
Advances - line of credit	12,970,788		10,754,764
Repayments - line of credit	(12,924,930)		(10,894,265)
Repayments - reducing revolving loan	(1,000,000)		(282,710)
Purchase and retirement of Common Stock	0		(8,860)
Common Stock cash dividends	0		(409,443)
Net cash used in financing activities	(954,142)		(840,514)
NET CHANGE IN CASH	46,971		35,165
CASH, beginning of period	157,923		258,801
CASH, end of period	204,894		293,966
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest	189,858		112,527
Cash paid for income taxes	0		3,500
Cash received for income taxes	0		85,000
NON-CASH ITEMS:
Repayments - line of credit with Compass Bank	$ 0		$ 10,617,598
[1]	The Company issued 12,500 shares of Common Stock under a settlement agreement with an activist shareholder group. The shares were valued at $175,000 based on the closing price of the Common Stock on the date of the grant.

UNAUDITED CONDENSED CONSOLIDATE

UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	6 Months Ended
	Jun. 30, 2017
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS [Abstract]
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	(1) UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The condensed consolidated financial statements included herein are unaudited and have been prepared by Birner Dental Management Services, Inc. (the “Company”) pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures included herein are adequate to make the information presented not misleading. A description of the Company’s accounting policies and other financial information is included in the audited consolidated financial statements as filed with the SEC in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the financial position of the Company as of June 30, 2017 and the results of operations and cash flows for the periods presented. All such adjustments are of a normal recurring nature. The results of operations for the quarter and six months ended June 30, 2017 are not necessarily indicative of the results that may be achieved for a full fiscal year and cannot be used to indicate financial performance for the entire year.

LIQUIDITY AND FINANCIAL RESOURC

LIQUIDITY AND FINANCIAL RESOURCES UPDATE	6 Months Ended
	Jun. 30, 2017
LIQUIDITY AND FINANCIAL RESOURCES UPDATE [Abstract]
LIQUIDITY AND FINANCIAL RESOURCES UPDATE	(2) LIQUIDITY AND FINANCIAL RESOURCES UPDATE The Company has historically operated with negative working capital and has been able to meet its current obligations as a result of strong operating cash flows and availability on its revolving lines of credit. Recent decreases in operating cash flows have led the Company to take certain actions. On July 21, 2017, the Company received notice of events of default and acceleration (the “Notice Letter”) from counsel to Guaranty Bank and Trust Company (the “Bank”) in connection with the Loan and Security Agreement, dated as of March 29, 2016, as amended by four amendments (collectively, the “Loan Agreement” or the “Credit Facility”), including the Fourth Amendment to Loan and Security Agreement and Forbearance Agreement dated March 30, 2017 (the “Forbearance Agreement”). The Notice Letter asserts events of default resulting from the Company’s failure to produce EBITDA of at least $870,000 for the second quarter of 2017 and to reduce the dollar amount of the outstanding reducing revolving loan by at least $500,000 on June 30, 2017. The Notice Letter further asserts that, as a result of these events of default, the following earlier events of default to which the Forbearance Agreement applied again exist: (i) the Company’s failure to maintain a Maximum Total Cash Flow Leverage Ratio of not more than 3.15x as of December 31, 2016; (ii) the Company’s failure to maintain a Fixed Charge Coverage Ratio of at least 1.35 to 1.00 as of December 31, 2016; and (iii) the Company’s failure to produce EBITDA of at least $650,000 for the fourth quarter of 2016. The Notice Letter further asserts that the Forbearance Period (as defined in the Forbearance Agreement) has terminated and that the Bank declares its commitments to the Company to be terminated and will charge interest on all obligations of the Company at the default rate effective as of December 31, 2016. In the Notice Letter, the Bank also declares all obligations of the Company to be immediately due and payable and demands payment in full of all obligations by no later than July 31, 2017. As of July 27, 2017, $9.3 million was outstanding under the Credit Facility. The Notice Letter further states that, although the Bank is not presently exercising its other rights and remedies available upon an event of default, it reserves its right to do so at any time in its sole discretion. Due to the above facts, all Bank debt is classified as a current liability on the balance sheet as of June 30, 2017. Under the Credit Facility and related pledge and security agreements, the Bank has liens and security interests on substantially all of the assets of the Company. The Company has commenced discussions with the Bank regarding a resolution of this matter. The failure to resolve this matter could have a material adverse effect on the Company, as the Bank could exercise its remedies under the Loan Agreement including foreclosure on the Company’s assets or take other actions. Due to the above issues, there is substantial doubt about the Company’s ability to continue as a going concern if no additional action takes place. The Company believes that any resolution with the Bank would involve financing to raise funds to pay down the outstanding principal on the Credit Facility or to refinance the Credit Facility. The Company has commenced discussions with potential investors and lenders and is exploring several funding options, including the issuance of additional equity or debt and the sale of certain dental practices. The Company believes it is probable that it will achieve a resolution with the Bank. However, there can be no assurance that the Company will be successful in completing the necessary financing or other transactions necessary to resolve this matter.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2017
SIGNIFICANT ACCOUNTING POLICIES [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	(3) SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation/Basis of Consolidation The accompanying condensed consolidated financial statements have been prepared on the accrual basis of accounting. These financial statements present the financial position and results of operations of the Company and the dental offices (“Offices”), which are under the control of the Company. The Offices are organized as professional corporations (“P.C.s”) and the Company provides business services to the Offices under long-term management agreements (the “Management Agreements”). All intercompany accounts and transactions have been eliminated in the consolidation. The Company treats Offices as consolidated subsidiaries where it has a long-term and unilateral controlling financial interest over the assets and operations of the Offices. The Company maintains control of substantially all of its Offices via the Management Agreements. The Company is a business service organization and does not engage in the practice of dentistry or the provision of dental hygiene services. These services are provided by licensed professionals. Certain key features of these arrangements either enable the Company at any time and in its sole discretion to cause a change in the shareholder of the P.C. (i.e., ''nominee shareholder'') or allow the Company to vote the shares of stock held by the owner of the P.C. and to elect a majority of the board of directors of the P.C. The accompanying condensed consolidated statements of operations reflect revenue, which is the amount billed to patients less contractual adjustments. Direct expenses consist of all the expenses incurred in operating the Offices and paid by the Company. Under the Management Agreements, the Company assumes responsibility for the management of most aspects of the Offices' business (the Company does not engage in the practice of dentistry or the provision of dental hygiene services), including personnel recruitment and training; comprehensive administrative, business and marketing support and advice; and facilities, equipment, and support personnel as required to operate the practices. The Company prepares its consolidated financial statements in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810, which provides for consolidation of variable interest entities (“VIEs”) of which the Company is the primary beneficiary. The Company has concluded that the P.C.s meet the definition of VIEs as defined by this standard and that the Company is the primary beneficiary of these VIEs. This conclusion was reached because the Company has the power to direct significant activities of the VIEs and the Company is obligated to absorb losses of and/or provide rights to receive benefits from the VIEs. Revenue Revenue is generally recognized when services are provided and is reported at estimated net realizable amounts due from insurance companies, preferred provider and health maintenance organizations (i.e., third-party payors) and patients for services rendered, net of contractual and other adjustments. Dental services are billed and collected by the Company in the name of the Offices. Revenue under certain third-party payor agreements is subject to audit and retroactive adjustments. To the Company’s knowledge, there are no material claims, disputes or other unsettled matters that exist concerning third-party reimbursements as of June 30, 2017. Most of the Company’s patients are insured under third-party payor agreements. The Company’s billing system generates contractual adjustments for each patient encounter based on fee schedules for the patient’s insurance plan. The services provided are attached to the patient’s fee schedule based on the insurance the patient has at the time the service is provided. Therefore, the revenue that is recorded by the billing system is based on insurance contractual amounts. Additionally, each patient at the time of service signs a form agreeing that the patient is ultimately responsible for the contracted fee if the insurance company does not pay the fee for any reason. Note Receivable A note receivable was created as part of a dental Office acquisition, of which approximately $49,743 in principal amount was outstanding at June 30, 2017. The note has equal monthly principal and interest amortization payments and a maturity date of October 31, 2018. The note bears interest at 6%, which is accrued monthly. If the note is uncollectible, an allowance for doubtful accounts will be created. There was no allowance for doubtful accounts for the note as of June 30, 2017 or December 31, 2016. Intangible Assets The Company's dental practice acquisitions involve the purchase of tangible and intangible assets and the assumption of certain liabilities of the acquired dental Offices. As part of the purchase price allocation, the Company allocates the purchase price to the tangible and identifiable intangible assets acquired and liabilities assumed, based on estimated fair market values. Costs of acquisition in excess of the net estimated fair value of tangible assets acquired and liabilities assumed are allocated to the Management Agreement related to the Office. The Management Agreement represents the Company's right to manage the Offices during the 40-year term of the Management Agreement. The assigned value of the Management Agreement is amortized using the straight-line method over a period of 25 years. Amortization remained constant at $211,000 for the quarters ended June 30, 2017 and 2016. Amortization remained constant at $422,000 for the six months ended June 30, 2017 and 2016. The Management Agreements cannot be terminated by a P.C. without cause, consisting primarily of bankruptcy or material default by the Company. If facts and circumstances indicate that the carrying value of long-lived and intangible assets may be impaired, the Company will perform an evaluation of recoverability. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset will be compared to the asset’s carrying amount to determine if a write-down to market value or discounted cash flow value is required. There were no impairment write-downs associated with the Company’s long-lived and intangible assets during the quarters ended June 30, 2017 and 2016. Stock-Based Compensation Expense The Company recognizes compensation expense on a straight line basis over the requisite service period of the award. Total stock-based compensation expense included in the Company’s condensed consolidated statements of operations for the quarters ended June 30, 2017 and 2016 was approximately $51,000 and $44,000, respectively, related to stock options. Total stock-based compensation expense included in the Company’s condensed consolidated statements of operations for the six months ended June 30, 2017 and 2016 was approximately $ 86,000 and $91,000, respectively, related to stock options. Total stock-based compensation expense was recorded as a component of corporate general and administrative expense. The Black-Scholes option-pricing model was used to estimate the option fair values. The option-pricing model requires a number of assumptions, of which the most significant are expected stock price volatility, the expected pre-vesting forfeiture rate, expected dividend rate and the expected option term (the amount of time from the grant date until the options are exercised or expire). Expected volatility was calculated based upon actual historical stock price movements over the most recent period ended June 30, 2017 equal to the expected option term. Expected pre-vesting forfeitures were estimated based on historical pre-vesting forfeitures over the most recent period ended June 30, 2017 for the expected option term. Recent Accounting Pronouncements In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). In March 2016, the FASB issued ASU No. 2016 -09, Improvements to Employee Share-Based Payment Accounting. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments. In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, In January 2017, the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment.

LOSS PER SHARE

LOSS PER SHARE	6 Months Ended
	Jun. 30, 2017
LOSS PER SHARE [Abstract]
LOSS PER SHARE	(4) LOSS PER SHARE The Company calculates earnings (loss) per share (“EPS”) in accordance with ASC Topic 260. Quarters Ended June 30, 2016 2017 Net Loss Shares Per Share Amount Net Loss Shares Per Share Amount Basic EPS $ (230,429 ) 1,860,261 $ (0.12 ) $ (901,274 ) 1,866,580 $ (0.48 ) Effect of Dilutive Stock Options - - - - - - Diluted EPS $ (230,429 ) 1,860,261 $ (0.12 ) $ (901,274 ) 1,866,580 $ (0.48 ) For the quarters ended June 30, 2017 and 2016, options to purchase 436,166 and 462,123 shares, respectively, of the Company’s common stock (“Common Stock”) were not included in the computation of diluted EPS because their effect was anti-dilutive. Six Months Ended June 30, 2016 2017 Net Loss Shares Per Share Amount Net Loss Shares Per Share Amount Basic EPS $ (330,840 ) 1,860,372 $ (0.18 ) $ (1,126,332 ) 1,863,746 $ (0.60 ) Effect of Dilutive Stock Options - - - - - - Diluted EPS $ (330,840 ) 1,860,372 $ (0.18 ) $ (1,126,332 ) 1,863,746 $ (0.60 ) For the six months ended June 30, 2017 and 2016, options to purchase 436,166 and 533,702 shares, respectively, of Common Stock were not included in the computation of diluted EPS because their effect was anti-dilutive.

STOCK-BASED COMPENSATION PLANS

STOCK-BASED COMPENSATION PLANS	6 Months Ended
	Jun. 30, 2017
STOCK-BASED COMPENSATION PLANS [Abstract]
STOCK-BASED COMPENSATION PLANS	(5) STOCK-BASED COMPENSATION PLANS The Company’s 2005 Equity Incentive Plan, as amended (“2005 Plan”), terminated on March 17, 2015. The 2005 Plan provided for the grant of incentive stock options, restricted stock, restricted stock units and stock grants to eligible employees (including officers and employee-directors) and non-statutory stock options to eligible employees, directors and consultants. As of June 30, 2017, there were 343,081 vested options and 51,585 unvested options granted under the 2005 Plan that remained outstanding in accordance with their terms and there were no shares available for issuance under the 2005 Plan due to its termination. The Company’s shareholders approved the 2015 Equity Incentive Plan (“2015 Plan”) in June 2015. The 2015 Plan replaces the 2005 Plan. The maximum number of shares of Common Stock that may be delivered to participants and their beneficiaries under the 2015 Plan is 200,000. The 2015 Plan provides for the grant of incentive stock options, stock appreciation right awards, restricted stock awards, stock unit awards and other stock-based awards to eligible recipients. The objectives of the 2015 Plan are to attract and retain the best possible candidates for positions of responsibility and provide for additional performance incentives by providing eligible employees with the opportunity to acquire equity in the Company. The 2015 Plan is administered by a committee of two or more outside directors from the Company’s Board of Directors (the “Committee”). The Committee determines the eligible individuals to whom awards under the 2015 Plan may be granted, as well as the time or times at which awards will be granted, the number of shares subject to awards to be granted to any eligible individual, the term of the award, vesting terms and conditions and any other terms and conditions of the grant in addition to those contained in the 2015 Plan. Each grant under the 2015 Plan will be confirmed by and subject to the terms of an award agreement. As of June 30, 2017, there were 16,750 vested options and 141,750 unvested options granted under the 2015 Plan. On June 20, 2017, the independent directors of the Board of Directors were granted 2,000 shares each of restricted Common Stock pursuant to the 2015 Plan. Fifty percent of the shares vest 12 months from the grant date, and the remaining shares vest 24 months from the grant date. As of June 30, 2017, 31,500 shares were available under the 2015 Plan. The Company uses the Black-Scholes option-pricing model to estimate the fair value of each option granted with the following weighted average assumptions: Quarters Ended June 30, Six Months Ended June 30, Valuation Assumptions 2016 (5) 2017 2016 2017 Expected life (1) - 4.97 3.25 4.58 Risk-free interest rate (2) - 1.75 % 1.21 % 1.79 % Expected volatility (3) - 50 % 39 % 50 % Expected dividend yield - 0.00 % 7.81 % 0.00 % Expected forfeiture (4) - 0.86 % 27.00 % 12.51 % (1) The expected life, in years, of stock options is estimated based on historical experience. (2) The risk-free interest rate is based on U.S. Treasury bills whose term is consistent with the expected life of the stock options. (3) The expected volatility is estimated based on historical and current stock price data for the Company. (4) Forfeitures are estimated based on historical experience. (5) The Company did not issue any options during the quarter ended June 30, 2016. A summary of option activity as of June 30, 2017, and changes during the six months then ended, is presented below: Number of Options Weighted- Average Exercise Price Range of Exercise Prices Weighted- Average Remaining Contractual Term (years) Aggregate Intrinsic Value (thousands) Outstanding at January 1, 2017 465,666 $ 15.94 $ 10.04 - $19.75 3.6 $ 654 Granted 87,500 $ 13.12 $ 12.25 - $14.45 Cancelled (13,000 ) $ 17.13 $ 17.13 - $17.13 Outstanding at June 30, 2017 540,166 $ 15.45 $ 10.04 - $19.75 3.8 $ 333 Exercisable at June 30, 2017 346,831 $ 17.00 $ 10.04 - $19.75 2.7 $ 93 The weighted average grant date fair value of options granted during the quarter ended June 30, 2017 was $5.68 per share. No options were granted during the quarter ended June 30, 2016. As of June 30, 2017, there was approximately $510,000 of total unrecognized compensation expense related to non-vested stock options, which is expected to be recognized over a weighted average period of 3.07 years and there was approximately $133,000 of total unrecognized compensation expense related to non -vested restricted Common Stock, which is expected to be recognized over a weighted average period of 1.97 years.

LINE OF CREDIT

LINE OF CREDIT	6 Months Ended
	Jun. 30, 2017
LINE OF CREDIT [Abstract]
LINE OF CREDIT	(6) LINE OF CREDIT The Credit Facility initially consisted of a $2.0 million revolving line of credit and a $10.0 million reducing revolving loan. The revolving line of credit matures on March 31, 2018. As amended by the March 2017 amendment, the revolving line of credit commitment reduces in four $300,000 increments during 2017 through maturity from $2.0 million to $800,000. The reducing revolving loan matures on March 31, 2021 and requires mandatory reductions of $500,000 per calendar quarter, with a further reduction on April 30, 2018 equal to the product of (i) 50% multiplied by (ii) EBITDA for 2017 minus capital expenditures for 2017, interest payments on the Credit Facility paid in 2017, $2.0 million, and cash taxes paid during 2017. Subject to any actions the Bank may take pursuant to the Notice Letter, the reducing revolving loan currently allows the Company to drawdown, repay and re-draw loans advanced to it within the available balance. Interest varies between LIBOR plus 3.10% and LIBOR plus 3.75% depending on the Company’s funded debt-to-EBITDA ratio. As of June 30, 2017, the revolving line of credit rate was 4.80% and the reducing revolving loan rate was 4.80%. At June 30, 2017, the Company had approximately $984,000 of borrowings outstanding under the revolving line of credit and approximately $416,000 available for borrowing under the revolving line of credit. Pursuant to the Notice Letter, the Bank states that it will charge interest at the default interest rate, LIBOR plus 5%, retroactively to December 31, 2016. At June 30, 2017, the Company had $8.0 million of borrowings outstanding under the reducing revolving loan. The Credit Facility is collateralized by substantially all of the assets of the Company. As amended by the March 2017 amendment, the Credit Facility requires the Company to maintain (i) a funded debt-to-EBITDA ratio of no more than 2.5 to 1.00 for the twelve months ending December 31, 2017 and thereafter, (ii) a fixed charge coverage ratio for the immediately preceding twelve months of not less than 1.25 to 1.00 for the quarter ending December 31, 2017 and each quarter thereafter, and (iii) to generate at least $870,000 of EBITDA in each of the first three quarters of 2017. In addition, capital expenditures may not exceed $180,000 per quarter. As a result of the March 2017 amendment to the Credit Facility, dividends and stock repurchases are not permitted under the Credit Facility. As disclosed in Note 2, the Company was not in compliance with the required $870,000 of EBITDA in the second quarter ended June 30, 2017 and did not make a required $500,000 payment at June 30, 2017 to decrease the reducing revolving loan from $ 8.0 million to $7.5 million. On July 21, 2017, the Company received the Notice Letter. The Company is taking the actions described in Note 2 to address the issues raised by the Notice Letter. Due to the above facts, all Bank debt is classified as current as of June 30, 2017.

DISCLOSURES ABOUT FAIR VALUE OF

DISCLOSURES ABOUT FAIR VALUE OF FINANCIAL INSTRUMENTS	6 Months Ended
	Jun. 30, 2017
DISCLOSURES ABOUT FAIR VALUE OF FINANCIAL INSTRUMENTS [Abstract]
DISCLOSURES ABOUT FAIR VALUE OF FINANCIAL INSTRUMENTS	(7) DISCLOSURES ABOUT FAIR VALUE OF FINANCIAL INSTRUMENTS ASC Topic 825, ''Disclosures About Fair Value of Financial Instruments,'' requires disclosure about the fair value of financial instruments. Carrying amounts for all financial instruments included in current assets and current liabilities approximate estimated fair values due to the short maturity of those instruments. The fair values of the Company's long-term debt are based on similar rates currently available to the Company. The Company believes the book value approximates fair value for the notes receivable. The Company follows ASC Topic 820, “Fair Value Measurements and Disclosures,” which defines fair value, establishes a framework for using fair value to measure assets and liabilities, and expands disclosures about fair value measurements. The statement establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions of what market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability of the inputs as follows: Level 1: Quoted prices are available in active markets for identical assets or liabilities. Level 2: Quoted prices in active markets for similar assets and liabilities that are observable for the asset or liability; or Level 3: Unobservable pricing inputs that are generally less observable from objective sources, such as discounted cash flow models or valuations. ASC Topic 820 requires financial assets and liabilities to be classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels. There were no transfers between the fair value hierarchy levels during the quarters ended June 30, 2017 and 2016. The following table represents the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2016 and June 30, 2017 by level within the fair value hierarchy: December 31, 2016 Fair Value Measurement Using June 30, 2017 Fair Value Measurement Using Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Contingent Liabilities Balance $ - - $ 321,000 $ - - $ 321,000 Contingent Liabilities As part of an Office acquisition completed in 2009, the Company recorded contingent liabilities to recognize an estimated amount to be paid as part of the acquisition agreement. These contingent liabilities are recorded at estimated fair values as of the date of acquisition, are payable upon the exercise of a put option by the seller beginning four years after the acquisition date and no later than ten years after the acquisition date, and are calculated at a multiple of the then trailing twelve-months operating cash flows. The Company remeasures the contingent liability to fair value each reporting date until the contingency is resolved. Any changes to the fair value are recognized into the income statement when determined. As of June 30, 2017, approximately $321,000 of contingent liabilities were recorded on the consolidated balance sheets in other long-term obligations.

STOCK ISSUANCE

STOCK ISSUANCE	6 Months Ended
	Jun. 30, 2017
STOCK ISSUANCE [Abstract]
STOCK ISSUANCE	(8) STOCK ISSUANCE During the quarter ended June 30, 2017, the Company issued 12,500 shares of Common Stock under a settlement agreement with an activist shareholder group. The shares were valued at $175,000 based on the closing price of the Common Stock on the date of the grant. On June 20, 2017, the independent directors of the Board of Directors were granted 2,000 shares each of restricted Common Stock pursuant to the 2015 Plan. Fifty percent of the shares vest 12 months from the grant date, and the remaining shares vest 24 months from the grant date.

SIGNIFICANT ACCOUNTING POLICI16

SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2017
SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Basis of Presentation/Basis of Consolidation	Basis of Presentation/Basis of Consolidation The accompanying condensed consolidated financial statements have been prepared on the accrual basis of accounting. These financial statements present the financial position and results of operations of the Company and the dental offices (“Offices”), which are under the control of the Company. The Offices are organized as professional corporations (“P.C.s”) and the Company provides business services to the Offices under long-term management agreements (the “Management Agreements”). All intercompany accounts and transactions have been eliminated in the consolidation. The Company treats Offices as consolidated subsidiaries where it has a long-term and unilateral controlling financial interest over the assets and operations of the Offices. The Company maintains control of substantially all of its Offices via the Management Agreements. The Company is a business service organization and does not engage in the practice of dentistry or the provision of dental hygiene services. These services are provided by licensed professionals. Certain key features of these arrangements either enable the Company at any time and in its sole discretion to cause a change in the shareholder of the P.C. (i.e., ''nominee shareholder'') or allow the Company to vote the shares of stock held by the owner of the P.C. and to elect a majority of the board of directors of the P.C. The accompanying condensed consolidated statements of operations reflect revenue, which is the amount billed to patients less contractual adjustments. Direct expenses consist of all the expenses incurred in operating the Offices and paid by the Company. Under the Management Agreements, the Company assumes responsibility for the management of most aspects of the Offices' business (the Company does not engage in the practice of dentistry or the provision of dental hygiene services), including personnel recruitment and training; comprehensive administrative, business and marketing support and advice; and facilities, equipment, and support personnel as required to operate the practices. The Company prepares its consolidated financial statements in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810, which provides for consolidation of variable interest entities (“VIEs”) of which the Company is the primary beneficiary. The Company has concluded that the P.C.s meet the definition of VIEs as defined by this standard and that the Company is the primary beneficiary of these VIEs. This conclusion was reached because the Company has the power to direct significant activities of the VIEs and the Company is obligated to absorb losses of and/or provide rights to receive benefits from the VIEs.
Revenue	Revenue Revenue is generally recognized when services are provided and is reported at estimated net realizable amounts due from insurance companies, preferred provider and health maintenance organizations (i.e., third-party payors) and patients for services rendered, net of contractual and other adjustments. Dental services are billed and collected by the Company in the name of the Offices. Revenue under certain third-party payor agreements is subject to audit and retroactive adjustments. To the Company’s knowledge, there are no material claims, disputes or other unsettled matters that exist concerning third-party reimbursements as of June 30, 2017. Most of the Company’s patients are insured under third-party payor agreements. The Company’s billing system generates contractual adjustments for each patient encounter based on fee schedules for the patient’s insurance plan. The services provided are attached to the patient’s fee schedule based on the insurance the patient has at the time the service is provided. Therefore, the revenue that is recorded by the billing system is based on insurance contractual amounts. Additionally, each patient at the time of service signs a form agreeing that the patient is ultimately responsible for the contracted fee if the insurance company does not pay the fee for any reason.
Note Receivable	Note Receivable A note receivable was created as part of a dental Office acquisition, of which approximately $49,743 in principal amount was outstanding at June 30, 2017. The note has equal monthly principal and interest amortization payments and a maturity date of October 31, 2018. The note bears interest at 6%, which is accrued monthly. If the note is uncollectible, an allowance for doubtful accounts will be created. There was no allowance for doubtful accounts for the note as of June 30, 2017 or December 31, 2016.
Intangible Assets	Intangible Assets The Company's dental practice acquisitions involve the purchase of tangible and intangible assets and the assumption of certain liabilities of the acquired dental Offices. As part of the purchase price allocation, the Company allocates the purchase price to the tangible and identifiable intangible assets acquired and liabilities assumed, based on estimated fair market values. Costs of acquisition in excess of the net estimated fair value of tangible assets acquired and liabilities assumed are allocated to the Management Agreement related to the Office. The Management Agreement represents the Company's right to manage the Offices during the 40-year term of the Management Agreement. The assigned value of the Management Agreement is amortized using the straight-line method over a period of 25 years. Amortization remained constant at $211,000 for the quarters ended June 30, 2017 and 2016. Amortization remained constant at $422,000 for the six months ended June 30, 2017 and 2016. The Management Agreements cannot be terminated by a P.C. without cause, consisting primarily of bankruptcy or material default by the Company. If facts and circumstances indicate that the carrying value of long-lived and intangible assets may be impaired, the Company will perform an evaluation of recoverability. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset will be compared to the asset’s carrying amount to determine if a write-down to market value or discounted cash flow value is required. There were no impairment write-downs associated with the Company’s long-lived and intangible assets during the quarters ended June 30, 2017 and 2016.
Stock-Based Compensation Expense	Stock-Based Compensation Expense The Company recognizes compensation expense on a straight line basis over the requisite service period of the award. Total stock-based compensation expense included in the Company’s condensed consolidated statements of operations for the quarters ended June 30, 2017 and 2016 was approximately $51,000 and $44,000, respectively, related to stock options. Total stock-based compensation expense included in the Company’s condensed consolidated statements of operations for the six months ended June 30, 2017 and 2016 was approximately $ 86,000 and $91,000, respectively, related to stock options. Total stock-based compensation expense was recorded as a component of corporate general and administrative expense. The Black-Scholes option-pricing model was used to estimate the option fair values. The option-pricing model requires a number of assumptions, of which the most significant are expected stock price volatility, the expected pre-vesting forfeiture rate, expected dividend rate and the expected option term (the amount of time from the grant date until the options are exercised or expire). Expected volatility was calculated based upon actual historical stock price movements over the most recent period ended June 30, 2017 equal to the expected option term. Expected pre-vesting forfeitures were estimated based on historical pre-vesting forfeitures over the most recent period ended June 30, 2017 for the expected option term.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). In March 2016, the FASB issued ASU No. 2016 -09, Improvements to Employee Share-Based Payment Accounting. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments. In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, In January 2017, the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment.

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2017
LOSS PER SHARE [Abstract]
Earnings (Loss) Per Share Calculation	The Company calculates earnings (loss) per share (“EPS”) in accordance with ASC Topic 260. Quarters Ended June 30, 2016 2017 Net Loss Shares Per Share Amount Net Loss Shares Per Share Amount Basic EPS $ (230,429 ) 1,860,261 $ (0.12 ) $ (901,274 ) 1,866,580 $ (0.48 ) Effect of Dilutive Stock Options - - - - - - Diluted EPS $ (230,429 ) 1,860,261 $ (0.12 ) $ (901,274 ) 1,866,580 $ (0.48 ) For the quarters ended June 30, 2017 and 2016, options to purchase 436,166 and 462,123 shares, respectively, of the Company’s common stock (“Common Stock”) were not included in the computation of diluted EPS because their effect was anti-dilutive. Six Months Ended June 30, 2016 2017 Net Loss Shares Per Share Amount Net Loss Shares Per Share Amount Basic EPS $ (330,840 ) 1,860,372 $ (0.18 ) $ (1,126,332 ) 1,863,746 $ (0.60 ) Effect of Dilutive Stock Options - - - - - - Diluted EPS $ (330,840 ) 1,860,372 $ (0.18 ) $ (1,126,332 ) 1,863,746 $ (0.60 )

STOCK-BASED COMPENSATION PLANS

STOCK-BASED COMPENSATION PLANS (Tables)	6 Months Ended
	Jun. 30, 2017
STOCK-BASED COMPENSATION PLANS [Abstract]
Estimated Fair Value Option Granted	The Company uses the Black-Scholes option-pricing model to estimate the fair value of each option granted with the following weighted average assumptions: Quarters Ended June 30, Six Months Ended June 30, Valuation Assumptions 2016 (5) 2017 2016 2017 Expected life (1) - 4.97 3.25 4.58 Risk-free interest rate (2) - 1.75 % 1.21 % 1.79 % Expected volatility (3) - 50 % 39 % 50 % Expected dividend yield - 0.00 % 7.81 % 0.00 % Expected forfeiture (4) - 0.86 % 27.00 % 12.51 % (1) The expected life, in years, of stock options is estimated based on historical experience. (2) The risk-free interest rate is based on U.S. Treasury bills whose term is consistent with the expected life of the stock options. (3) The expected volatility is estimated based on historical and current stock price data for the Company. (4) Forfeitures are estimated based on historical experience. (5) The Company did not issue any options during the quarter ended June 30, 2016.
Summary of Option Activity	A summary of option activity as of June 30, 2017, and changes during the six months then ended, is presented below: Number of Options Weighted- Average Exercise Price Range of Exercise Prices Weighted- Average Remaining Contractual Term (years) Aggregate Intrinsic Value (thousands) Outstanding at January 1, 2017 465,666 $ 15.94 $ 10.04 - $19.75 3.6 $ 654 Granted 87,500 $ 13.12 $ 12.25 - $14.45 Cancelled (13,000 ) $ 17.13 $ 17.13 - $17.13 Outstanding at June 30, 2017 540,166 $ 15.45 $ 10.04 - $19.75 3.8 $ 333 Exercisable at June 30, 2017 346,831 $ 17.00 $ 10.04 - $19.75 2.7 $ 93

DISCLOSURES ABOUT FAIR VALUE 19

DISCLOSURES ABOUT FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)	6 Months Ended
	Jun. 30, 2017
DISCLOSURES ABOUT FAIR VALUE OF FINANCIAL INSTRUMENTS [Abstract]
Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table represents the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2016 and June 30, 2017 by level within the fair value hierarchy: December 31, 2016 Fair Value Measurement Using June 30, 2017 Fair Value Measurement Using Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Contingent Liabilities Balance $ - - $ 321,000 $ - - $ 321,000

LIQUIDITY AND FINANCIAL RESOU20

LIQUIDITY AND FINANCIAL RESOURCES UPDATE (Details) $ in Thousands	Jul. 21, 2017Amendment	Dec. 31, 2016USD ($)	Jun. 30, 2017USD ($)	Dec. 31, 2016	Jul. 27, 2017USD ($)
Long-term Debt [Line Items]
Minimum EBITDA amount			$ 870
Subsequent Event [Member]
Long-term Debt [Line Items]
Number of amendments made | Amendment	4
Amount outstanding					$ 9,300
Revolving Credit Facility [Member]
Long-term Debt [Line Items]
Amount outstanding			$ 500
Line of Credit [Member] | Maximum [Member]
Long-term Debt [Line Items]
Cash flow leverage ratio				3.15
Line of Credit [Member] | Minimum [Member]
Long-term Debt [Line Items]
Fixed charge coverage ratio		1.35	1.25
Amount of generated EBITDA		$ 650

SIGNIFICANT ACCOUNTING POLICI21

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Note Receivable [Abstract]
Outstanding principal amount of note receivables	$ 49,473		$ 49,473
Maturity date			Oct. 31, 2018
Interest rate on notes receivable			6.00%
Allowance for doubtful accounts	0		$ 0		$ 0
Intangible Assets [Abstract]
Life of the management agreement			40 years
Amortization period for contract			25 years
Amortization expense	211,000	$ 211,000	$ 422,000	$ 422,000
Impairment of Long-Lived and Intangible Assets [Abstract]
Impairment of long-lived and intangible assets	0	0
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 51,000	$ 44,000	$ 86,000	$ 91,000

LOSS PER SHARE (Details)

LOSS PER SHARE (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Net loss, diluted [Abstract]
Net loss, basic EPS	$ (901,274)	$ (230,429)	$ (1,126,332)	$ (330,840)
Effect of dilutive stock options	0	0	0	0
Net loss, diluted EPS	$ (901,274)	$ (230,429)	$ (1,126,332)	$ (330,840)
Weighted average number of shares outstanding reconciliation [Abstract]
Weighted average number of shares, basic EPS (in shares)	1,866,580	1,860,261	1,863,746	1,860,372
Effect of dilutive stock options, shares (in shares)	0	0	0	0
Weighted average number of shares outstanding, diluted EPS (in shares)	1,866,580	1,860,261	1,863,746	1,860,372
Earnings per share, basic and diluted [Abstract]
Per share amount - basic EPS (in dollars per share)	$ (0.48)	$ (0.12)	$ (0.60)	$ (0.18)
Effect of dilutive stock option (in dollars per share)	0	0	0	0
Per share amount - diluted EPS (in dollars per share)	$ (0.48)	$ (0.12)	$ (0.60)	$ (0.18)
Antidilutive securities (in shares)	436,166	462,123	436,166	533,702

STOCK-BASED COMPENSATION PLAN23

STOCK-BASED COMPENSATION PLANS (Details) $ / shares in Units, $ in Thousands		Jun. 20, 2017shares	Jun. 30, 2017USD ($)Administrator$ / sharesshares	Jun. 30, 2016	[2]	Jun. 30, 2017USD ($)Administrator$ / sharesshares	Jun. 30, 2016$ / shares	Dec. 31, 2016USD ($)$ / sharesshares
Fair value assumptions [Abstract]
Expected life	[1]		4 years 11 months 19 days			4 years 6 months 29 days	3 years 3 months
Risk-free interest rate	[3]		1.75%			1.79%	1.21%
Expected volatility	[4]		50.00%			50.00%	39.00%
Expected dividend yield			0.00%			0.00%	7.81%
Expected forfeiture	[5]		0.86%			12.51%	27.00%
Stock Option [Member]
Options outstanding [Roll Forward]
Outstanding, beginning (in shares) | shares						465,666
Granted (in shares) | shares						87,500
Cancelled (in shares) | shares						(13,000)
Outstanding, ending (in shares) | shares			540,166			540,166		465,666
Exercisable (in shares) | shares			346,831			346,831
Options weighted average exercise price [Roll Forward]
Outstanding, beginning (in dollars per share)						$ 15.94
Granted (in dollars per share)						13.12
Cancelled (in dollars per share)						17.13
Outstanding, ending (in dollars per share)			$ 15.45			15.45		$ 15.94
Exercisable (in dollars per share)			$ 17			$ 17
Options, additional disclosures [Abstract]
Outstanding, weighted average remaining contractual term						3 years 9 months 18 days		3 years 7 months 6 days
Outstanding, aggregate intrinsic value | $			$ 333			$ 333		$ 654
Exercisable, weighted average remaining contractual term						2 years 8 months 12 days
Exercisable, aggregate intrinsic value | $			93			$ 93
Weighted average grant date fair value of options (in dollars per share)						$ 5.68	$ 0
Total unrecognized compensation expense | $			$ 510			$ 510
Weighted average period for recognition						3 years 25 days
Stock Option [Member] | Minimum [Member]
Range of Exercise Prices [Abstract]
Outstanding, beginning of period (in dollars per share)						$ 10.04
Granted (in dollars per share)						12.25
Cancelled (in dollars per share)						17.13
Outstanding, end of period (in dollars per share)			$ 10.04			10.04		$ 10.04
Exercisable (in dollars per share)			10.04			10.04
Stock Option [Member] | Maximum [Member]
Range of Exercise Prices [Abstract]
Outstanding, beginning of period (in dollars per share)						19.75
Granted (in dollars per share)						14.45
Cancelled (in dollars per share)						17.13
Outstanding, end of period (in dollars per share)			19.75			19.75		$ 19.75
Exercisable (in dollars per share)			$ 19.75			$ 19.75
Restricted Stock [Member]
Options, additional disclosures [Abstract]
Total unrecognized compensation expense | $			$ 133			$ 133
Weighted average period for recognition						1 year 11 months 19 days
2005 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested options (in shares) | shares			343,081			343,081
Unvested options (in shares) | shares			51,585			51,585
2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Minimum number of plan administrators | Administrator			2			2
Vested options (in shares) | shares			16,750			16,750
Unvested options (in shares) | shares			141,750			141,750
Maximum number of shares of Common Stock that can be delivered under the plan (in shares) | shares			200,000			200,000
Shares available for issuance (in shares) | shares			31,500			31,500
2015 Plan [Member] | Restricted Stock [Member]
Options outstanding [Roll Forward]
Granted (in shares) | shares		2,000
Options, additional disclosures [Abstract]
Percentage of vested shares in next 12 months		50.00%
Percentage of vested shares in next 24 months		50.00%
[1]	The expected life, in years, of stock options is estimated based on historical experience.
[2]	The Company did not issue any options during the quarter ended June 30, 2016.
[3]	The risk-free interest rate is based on U.S. Treasury bills whose term is consistent with the expected life of the stock options.
[4]	The expected volatility is estimated based on historical and current stock price data for the Company.
[5]	Forfeitures are estimated based on historical experience.

LINE OF CREDIT (Details)

LINE OF CREDIT (Details)	Mar. 29, 2016USD ($)	Dec. 31, 2016	Jun. 30, 2017USD ($)	Dec. 31, 2016
Line of Credit [Member] | Maximum [Member]
Long-term Debt [Line Items]
Debt To EBITDA ratio for the twelve months ending December 31, 2017 and thereafter			2.5
Capital expenditure per quarter			$ 180,000
Line of Credit [Member] | Minimum [Member]
Long-term Debt [Line Items]
Fixed charge coverage ratio		1.35	1.25
Amount of generated EBITDA required to comply with covenant in each of first three quarters of 2017			$ 870,000
Domestic Line Of Credit Due March 2018 [Member]
Long-term Debt [Line Items]
Maximum borrowing capacity	$ 2,000,000		800,000
Amount available for borrowing			984,000
Revolving line of credit commitment reduction amount			$ 300,000
Line of credit interest rate			4.80%
Maturity date			Mar. 31, 2018
Domestic Line Of Credit Due March 2021 [Member]
Long-term Debt [Line Items]
Amount outstanding	10,000,000		$ 8,000,000
Amount available for borrowing			$ 416,000
Quarterly payment of loan payable	$ 500,000
Reduction in EBITDA percentage			50.00%
Interest payment on credit facility			$ 2,000,000
Line of credit interest rate			4.80%
Maturity date			Mar. 31, 2021
Quarterly payment of loan payable due			$ 500,000
Decrease in revolving loan facility			$ 7,500,000
LIBOR Borrowing Rate [Member] | Domestic Line Of Credit Due March 2018 [Member]
Long-term Debt [Line Items]
Basis spread on variable rate				5.00%
LIBOR Borrowing Rate [Member] | Domestic Line Of Credit Due March 2018 [Member] | Maximum [Member]
Long-term Debt [Line Items]
Basis spread on variable rate			3.75%
LIBOR Borrowing Rate [Member] | Domestic Line Of Credit Due March 2018 [Member] | Minimum [Member]
Long-term Debt [Line Items]
Basis spread on variable rate			3.10%
LIBOR Borrowing Rate [Member] | Domestic Line Of Credit Due March 2021 [Member]
Long-term Debt [Line Items]
Basis spread on variable rate				5.00%
LIBOR Borrowing Rate [Member] | Domestic Line Of Credit Due March 2021 [Member] | Maximum [Member]
Long-term Debt [Line Items]
Basis spread on variable rate			3.75%
LIBOR Borrowing Rate [Member] | Domestic Line Of Credit Due March 2021 [Member] | Minimum [Member]
Long-term Debt [Line Items]
Basis spread on variable rate			3.10%

DISCLOSURES ABOUT FAIR VALUE 25

DISCLOSURES ABOUT FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - USD ($)	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Contingent Liabilities [Abstract]
Number of trailing months of operating cash flow used to determine contingent liability	12 months
Minimum [Member]
Contingent Liabilities [Abstract]
Number of years until the contingent liability becomes payable	4 years
Maximum [Member]
Contingent Liabilities [Abstract]
Number of years until the contingent liability becomes payable	10 years
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Liabilities, Fair Value Disclosure [Abstract]
Contingent Liabilities Balance	$ 0	$ 0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Liabilities, Fair Value Disclosure [Abstract]
Contingent Liabilities Balance	0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Liabilities, Fair Value Disclosure [Abstract]
Contingent Liabilities Balance	$ 321,000	$ 321,000

STOCK ISSUANCE (Details)

STOCK ISSUANCE (Details) - USD ($)	Jun. 20, 2017	Jun. 30, 2017	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issued (in shares)		12,500
Value of common stock issued		$ 175,000	$ 175,000
2015 Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	2,000
Percentage of vested shares in next 12 months	50.00%
Percentage of vested shares in next 24 months	50.00%